Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients

Zaza, Gianluigi; Granata, Simona; Sallustio, Fabio; Grandaliano, Giuseppe; Schena, Francesco Paolo

doi:10.1111/j.1365-2249.2009.04065.x

Cited by 24 publications

(19 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In conclusion, Immunology and our sister journal Clinical and Experimental Immunology are strongly committed to publishing high-quality research relating to new therapeutics [9][10][11][12][13][14][15][16] as well as to the provision of educational resources, and therefore we recommend the GtoImmuPdb database as a novel tool to accelerate research, education and drug discovery in immunology, infection and inflammation.…”

Section: Discussionmentioning

confidence: 99%

Guide to Immunopharmacology: a database to boost immunology education, research and therapy

Milling

Spedding²,

Maffia

2020

Immunology

View full text Add to dashboard Cite

Summary In the era of big data, the establishment of a free database, containing all the immune drug targets and associated cell types, is of great value. To this aim, the Guide to Immunopharmacology has been created in a joint effort between the International Union of Basic and Clinical Pharmacology (IUPHAR) and the International Union of Immunological Societies (IUIS). Here we highlight the structure and content of the database, which includes up‐to‐date quantitative information on the fundamental science underlying each immune target. A set of practical examples and tools for data mining are summarized to support immune research into drug discovery and therapeutics.

show abstract

Section: Discussionmentioning

confidence: 99%

Guide to Immunopharmacology: a database to boost immunology education, research and therapy

Milling

Spedding²,

Maffia

2020

Immunology

View full text Add to dashboard Cite

show abstract

“…In helping pharma ceutical firms, it offers a potential advantage to the European and UK industry, and at a time of almost unprecedented economic crisis, that is important. However, it is also clear that the full benefits of PGx are a long way from being realized [2,3].…”

Section: Pharmacogenomics: Where Does Britain Stand?mentioning

confidence: 97%

Pharmacogenomics: Where does Britain Stand?

Hudson

2011

Pharmacogenomics

View full text Add to dashboard Cite

“…Several novel and existing therapeutic modalities have been featured [100][101][102][103][104][105][106], as well as treatment challenges [107], including the complications of tumour necrosis factor (TNF)-a blockade [108] and the hurdles faced when considering novel combination immunotherapies for autoimmune diseases such as type 1 diabetes [109]. Pharmacogenomics is an allied and emerging concept in therapeutics [110]. Natural immune modulators based on parasites are the focus of many groups' research [111].…”

Section: Novel Therapeuticsmentioning

confidence: 99%

Broadening the translational immunology landscape

Peakman

2012

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryIt is just over 5 years since Clinical and Experimental Immunology came under the direction of a new team of Editors and made a concerted effort to refresh its approach to promoting clinical and applied immunology through its pages. There were two major objectives: to foster papers in a field which, at the time, we loosely termed 'translational immunology'; and to create a forum for the presentation and discussion of immunology that is relevant to clinicians operating in this space. So, how are we doing with these endeavours? This brief paper aims to summarize some of the key learning points and successes and highlight areas in which translational gaps remain. Keywords Gathering opinionsOne of the better ways to serve the clinical and experimental immunology community has proved to be in asking it to provide reviews, opinion pieces, disease guidelines and high-level, 'best-practice' essays aimed at postgraduate training and beyond. These latter have proved a considerable success, and we have now published more than 13 of these papers in a series describing the approach to patients with different immune-mediated conditions [1][2][3]. These papers have also become a publicly accessible resource through the British Society for Immunology website [4]. This concept has spawned a further wave of recent review papers focusing similarly on 'immunology in the clinic' , which have also proved to be of major interest to readers, attracting thousands of downloads [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]. Papers that provide guidelines and disease classifications to practising clinical immunologists and rheumatologists are an important part of this dissemination process, and here we have particularly promoted areas such as the vasculitides [3,[23][24][25][26][27][28][29] and primary immunodeficiency [30][31][32][33]. Clinical immunology in practiceThe journal has also welcomed regular research papers that have addressed important topics in the translational pathway. Various aspects of clinical care in primary immunodeficiency have been highlighted, including patient and research databases, patient-centric screening protocols, clinical uses of immunoglobulin replacement and health economics [34][35][36][37][38][39][40][41][42]. The journal is striving to become a key forum for these issues, especially in disease settings that are niche areas for clinical immunologists, such as immunodeficiency, and therefore do not otherwise have clear publishing outlets. We have also highlighted emerging fields, including tumour immunotherapy [14][15][16][17]43,44] and the autoinflammatory diseases [11][12][13], as well as the more traditional domains of the translational immunologist, such as allergy [18,22,45]. Clinically relevant advances in cell separation technology and the identification of pathogenic T cells in autoimmunity and inflammation have also been featured [46][47][48]. New insights into immunopathologyOne of the strengths of the journal is the prevailing interest in underlying cellular and m...

show abstract

Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients

Cited by 24 publications

References 113 publications

Guide to Immunopharmacology: a database to boost immunology education, research and therapy

Guide to Immunopharmacology: a database to boost immunology education, research and therapy

Pharmacogenomics: Where does Britain Stand?

Broadening the translational immunology landscape

Contact Info

Product

Resources

About